Current clinical trials in retinoblastoma include:
EudraCT Number: 2011-006109-85
Sponsor Protocol Number: RTBAIEOP012
Start Date: 2012-02-14
Sponsor Name:
A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
Full Title:
DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012
Medical condition:Newly diagnosed retinoblastoma patientsDisease:
Version 14.1
SOC Term 10010331 - Congenital, familial and genetic disorders
Classification Code 10038916
Term Retinoblastoma
Level PT
Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18
Gender: Male, Female
Trial protocol: IT (Ongoing)Trial results: (No results available)
Clinical trial Number: NCT02329002
Full Title: Multicentric implementation of MR imaging in irradiated hereditary RB survivors
Objective:For the evaluation of the value of craniofacial MRI screening for early detection of second craniofacial primary tumours and to enhance survival
Status:Not recruiting
Prinicipal investigator Pim de Graaf
RB-Registry: clinical registry for prospective data on retinoblastoma epidemiology and clinical course
Funded by Deutsche Kinderkrebsstiftung. Our aim with the RB-Registry is to gather epidemiological and clinical data on pediatric eye tumors to develop a knowledge base. The knowledge gathered within RB-Registry will improve counseling for newly diagnosed patients and will provide a base for the development of interventional clinical trials to improve early diagnosis, treatment and follow-up for retinoblastoma patients. RB-Registry provides a consultation hotline and reference evaluations. The database and a biobank will support accompanying biological studies. The long-term perspective of RB-Registry is to improve survival rates in advanced tumor stages to reduce late effects and improve the quality of life of survivors.
Inclusion criteria:Patients newly diagnosed with retinoblastoma or other pediatric eye tumors and children with newly diagnosed RB1 germline mutation who are residents of Germany and Austria and have not received prior treatment for retinoblastoma
Objectives:The primary objective is to evaluate the exact retinoblastoma group (ICRB) and stage (IRSS) distribution in Germany and Austria
Prinicpal Investigator: Dr Petra Temming
EudraCT Number: 2009-016448-38
Sponsor Protocol Number: IC 2009-04
Start Date: 2009-12-15
Sponsor Name:
Institut Curie
Full Title:
Traitement adjuvant dans les rétinoblastomes unilatéraux étendus énucléés d’emblée.
Medical condition:
Rétinoblastomes unilatéraux étendus énucléés d’emblée.
Disease:
Version 12.0
SOC Term
Classification Code 10038916
Term Retinoblastoma
Level LLT
Population Age: Newborns, Infants and toddlers, Children, Under 18
Gender: Male, Female
Trial protocol: FR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2012-002825-31
Sponsor Protocol Number: : INTV-STC-RT-SI-2012
Start Date: 2012-07-01
Sponsor Name:
AZIENDA OSPEDALIERA SENESE
Full Title:
NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: INTRAVITREAL AND SUBCONJUNCITIVAL INJECTION OF CHEMOTHERAPY in the intraoculars RTBs
Medical condition:
patients with RTB
Disease:
Version 14.1
SOC Term10015919 - Eye disorders
Classification Code 10030054
Term Ocular neoplasms
Level HLGT
Disease:
Version 14.1
SOC Term10015919 - Eye disorders
Classification Code 10015919
Term Eye disorders
Level SOC
Population Age:Newborns, Infants and toddlers, Children, Under 18
Gender: Male, Female
Trial protocol: FR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2016-001060-11
Sponsor Protocol Number: : FSJD-RTB-2015
Start Date: 2017-08-03
Sponsor Name:Fundació Sant Joan de Déu
Full Title:A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma
Medical condition:refractory retinoblastoma Disease:Version 14.1 SOC Term10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) Classification Code 10038916 Term RetinoblastomaLevel PT